# Atrium Therapeutics, Inc. (RNA)

> Source: Nexqual · https://nexqual.com/RNA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Atrium Therapeutics, Inc. (RNA), nexqual.com/RNA" · informational, not investment advice.

**Price:** USD 7.82 (+1.82% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7.68 · day 7.65–7.87 · 52w 7.54–16.77 · market cap $134M · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 25 (range 25–25).
- Total return with dividends: 1Y -47.0% vs S&P 500 +18.1%; 5Y -47.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.67, revenue estimate $11.3M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 25 (low 25, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-08-06 | HC Wainwright & Co. | Initiated | Buy | $25 |
| 2026-06-18 | Cantor Fitzgerald | Initiated | Overweight | $25 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-02-27) | 5Y (from 2026-02-23) |
|---|---|---|
| Total return | -47.0% | -47.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 54.5% | 56.0% |
| Max drawdown | -53.6% (Mar 2026→Oct 2026) | -47.2% (Mar 2026→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/RNA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt